Clinical Trial Update: An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

Open-label Phase 1 study of once-daily oral tivozanib (AV-951) in subjects with non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tivozanib (tivozanib)

Snippet

Sponsor: AVEO Pharmaceuticals, Inc. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: COMPLETED